CAR T-cell therapy effective for relapsed mantle cell lymphoma patients

(University of Texas M. D. Anderson Cancer Center) A one-year follow-up study revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) .
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news